Semaglutide — 30 mg

Description

Semaglutide is a synthetic GLP-1 analogue with high homology to human GLP-1 that acts biochemically as a GLP-1 receptor agonist, originated by Novo Nordisk. It has been approved and marketed as a pharmaceutical (Ozempic, Wegovy, Rybelsus); it is supplied here solely as a lyophilized research chemical.

Research context: In published laboratory and preclinical research, semaglutide has been studied in the context of GLP-1 receptor signaling and metabolic-regulation pathways.

Specifications: Molecular mass 4113.58 Da; CAS 910463-68-2; purity 99.8% (HPLC); 30 mg lyophilized powder in a sealed vial; storage −20°C (24 months).

This product is supplied strictly for in-vitro laboratory research. It is not a drug, food, cosmetic, or dietary supplement, and is not intended for human or animal consumption, medical, veterinary, or household use.